Format

Send to

Choose Destination
Ann Allergy Asthma Immunol. 2010 Nov;105(5):387-93. doi: 10.1016/j.anai.2010.08.015.

The safety of the H1N1 influenza A vaccine in egg allergic individuals.

Author information

1
Division of Allergy and Clinical Immunology, The University of Michigan Health Systems, Ann Arbor, Michigan 48106, USA. mgreenha@med.umich.edu

Abstract

BACKGROUND:

The safety of H1N1 vaccine is unknown in egg allergic (EA) recipients.

OBJECTIVES:

To establish the safety of administering H1N1 vaccine and to evaluate the predictability of H1N1 skin testing in EA patients.

METHODS:

In a controlled, prospective trial, H1N1 skin testing and vaccination was compared between EA patients (n = 105) and non-EA controls (n = 19). Those with negative H1N1 skin test results received a full H1N1 dose; those with a positive skin test result received a graded challenge (10%, 90%). Booster vaccine, if required, was given as a single dose from a different lot without prior testing.

RESULTS:

Prick and intradermal test results were positive in 3 (2.4%) of 124 and 41 (33.1%) of 124 study participants, respectively. Forty-one individuals received a 2-step graded vaccine challenge, including 13 of 25 with a history of egg anaphylaxis. No significant allergic reactions resulted from either method of vaccination or from subsequent booster doses.

CONCLUSION:

All study participants received the H1N1 vaccine without significant allergic reactions. Skin testing is unnecessary and does not predict vaccine tolerance. All study participants who received a graded challenge tolerated a single dose booster from a different, untested lot, including 7 individuals with a history of egg-induced anaphylaxis. We recommend administration of H1N1 vaccine to EA children without prior skin testing or graded challenge dosing.

PMID:
21055666
DOI:
10.1016/j.anai.2010.08.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center